Tirzepatide

The Tirzepatide evidence base cited here is 7 sources — 4 clinical, 2 regulatory. Its strongest evidence is human — 4 clinical studies, most recently 2023 ("Tirzepatide Once Weekly for the Treatment of Obesity in People with Type…"). Regulatory status: FDA-approved (Mounjaro/Zepbound).

Cross-trial comparison only — populations, durations, and endpoints differ, and only tirzepatide vs semaglutide has been tested head-to-head (SURPASS-2).

*Retatrutide's 28.7% figure is reported topline, pending peer-reviewed publication. See the retatrutide and semaglutide research pages for the full breakdowns. All three are built on the same His-Aib-Glu-Gly-Thr-Phe… N-terminal incretin backbone — what differs is the receptor targets (GLP-1 → +GIP → +glucagon), the fatty-acid chain and half-life (~7 / ~5 / ~6 days), and peak efficacy.

• Tirzepatide is an FDA-approved dual GIP/GLP-1 receptor agonist from Eli Lilly, sold as Mounjaro (type 2 diabetes, 2022) and Zepbound (weight management, 2023; obstructive sleep apnea, 2024).
• It produced the largest weight loss of any approved obesity drug to date — 22.5% mean reduction at the 15 mg dose over 72 weeks in SURMOUNT-1 (NEJM, trial product estimand).
• In the head-to-head SURPASS-2 trial it beat semaglutide 1 mg on both HbA1c and weight loss in type 2 diabetes.

Tirzepatide is a once-weekly injectable peptide that activates two incretin receptors — GIP and GLP-1 — at the same time. That dual mechanism is what separates it from earlier single-target GLP-1 drugs like semaglutide and liraglutide, and it translated into the strongest weight-loss results of any approved medication when SURMOUNT-1 reported a 22.5% mean reduction at the top dose.

Unlike retatrutide (still investigational), tirzepatide is fully FDA-approved — as Mounjaro for type 2 diabetes, Zepbound for chronic weight management, and Zepbound for obstructive sleep apnea in adults with obesity. The clinical evidence base behind it is among the deepest of any peptide therapeutic.

Tirzepatide is a synthetic 39-amino-acid peptide that binds and activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor — the two incretin hormones that govern after-meal insulin release, appetite, and energy balance.

Engaging both receptors produces additive and in some pathways synergistic effects on blood sugar and body weight that GLP-1 activation alone cannot match — the central reason it outperformed semaglutide in direct comparison.

By mass it is a ~4,814 Da peptide carrying a C20 fatty-diacid chain that binds albumin and extends its action, enabling once-weekly dosing. After a subcutaneous dose, plasma levels peak at roughly 1 day, the half-life is ~5 days, and the compound is largely cleared within about 25 days.

Tirzepatide is injected subcutaneously once weekly. The label uses a stepped titration to let the gut adapt and limit nausea:

• Weeks 1–4: 2.5 mg/week (starting dose, not therapeutic)
• Weeks 5–8: 5 mg
• Weeks 9–12: 7.5 mg
• Weeks 13–16: 10 mg
• Weeks 17–20: 12.5 mg
• Week 21+: 15 mg (maximum)

Not everyone needs the 15 mg max — many reach their target at 5 or 10 mg with fewer side effects. Stretching each step to 6–8 weeks (rather than 4) is commonly used to cut GI side effects without losing long-term efficacy. Minimum 72 hours between doses if the weekly day shifts.

• Weeks 1–4: ~2–4% weight loss; appetite suppression often starts in week one
• Weeks 4–12: ~5–10% loss; glycemic improvements appear by weeks 4–8
• Weeks 12–24: ~15–18% at higher doses
• Weeks 24–72: up to ~22.5% mean at 15 mg, typically plateauing around weeks 52–72

Well-characterized across thousands of trial participants; dominated by dose-dependent gastrointestinal effects that peak during escalation.

Usually used standalone, occasionally combined in clinical practice. Research context, not protocol advice.

• Metformin — the most common pairing in T2D; different mechanism, well tolerated.
• SGLT2 inhibitors (empagliflozin, dapagliflozin) — add ~2–3 kg of loss plus cardiorenal protection.
• Testosterone (in hypogonadal men) — may help preserve lean mass during rapid weight loss.
• NOT advised: other GLP-1 agonists (overlapping mechanism, more side effects), or insulin without careful dose reduction (hypoglycemia risk).

Drug interaction: tirzepatide's delayed gastric emptying can reduce absorption of oral contraceptives — a barrier method (or non-oral contraceptive) is advised for 4 weeks after starting and after each dose increase.

• Mounjaro/Zepbound pens: refrigerate at 2–8°C; up to 21 days at room temp (≤30°C); protect from light; don't freeze; don't use if cloudy or particulate.
• Research-grade lyophilized powder: reconstitute with bacteriostatic water added down the vial wall, swirl (don't shake); refrigerate the solution at 2–8°C and use within ~28 days; protect from light; avoid freeze-thaw.

• Mounjaro — approved May 2022 for type 2 diabetes (adjunct to diet/exercise).
• Zepbound — approved Nov 2023 for chronic weight management (BMI ≥30, or ≥27 with a comorbidity).
• Zepbound (OSA) — approved 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity (SURMOUNT-OSA).
• Compounded tirzepatide is increasingly restricted now that the shortage has resolved and the FDA is enforcing against copies of an approved drug.

Research-grade tirzepatide from peptide suppliers is for laboratory research only — not approved for human use outside a prescription.

As of 2026, GLP-1 agonists including tirzepatide are on WADA's monitoring program but not prohibited — there are no current sanctions for use. The monitoring status means it's being evaluated for possible future prohibition, so athletes should confirm the current year's list with their anti-doping authority and seek a TUE where a diagnosed condition applies.

On the Huberman Lab podcast, Dr. Abud Bakri used the GLP-1 class to make his central point that 'peptide' is a useless category: orforglipron (a non-peptide oral) is functionally closer to tirzepatide than BPC-157 (a peptide) is — what matters is the receptor, not the chemical class. Tirzepatide's dual GIP + GLP-1 mechanism is what distinguishes it from semaglutide.

He also surfaced economics most patients never hear: compounding markups are often pocketed by the prescribing clinician (a pharmacy may charge ~$150/vial while the patient is charged $200–$800), and patients are within their rights to ask what their provider paid. As with the whole class, his framing was cautious optimism plus an honest 'long-term unknown.'

Expert commentary on mechanism and on the market economics of compounded GLP-1s.

All citations link to the original source (PubMed, journal site, or regulatory filing). Independent research database — no vendor influence on what's cited.